Bayesian Capital Management, LP Glaukos Corp Transaction History

Bayesian Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$43.88 - $52.48 $256,566 - $306,850	5,847 New	5,847 $292,000
Q3 2022 Nov 14, 2022	BUY	$46.84 - $58.49 $304,694 - $380,477	6,505 New	6,505 $346,000
Q3 2019 Nov 13, 2019	SELL	$58.58 - $83.91 $292,431 - $418,878	-4,992 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$63.59 - $78.71 $88,517 - $109,564	1,392 Added 38.67%	4,992 $376,000
Q1 2019 May 14, 2019	BUY	$50.75 - $80.54 $182,700 - $289,944	3,600 New	3,600 $282,000

354

50M

282K

401K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.28B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.